Stay updated on Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page
- Check6 days agoChange DetectedRemoved the primary disease term 'Head and neck squamous cell carcinoma' and the related topic 'MedlinePlus Genetics' from the page, while updating the revision note from v3.3.1 to v3.3.2.SummaryDifference0.2%

- Check13 days agoChange DetectedAdded related topics including Head and neck squamous cell carcinoma and MedlinePlus Genetics, and updated the PubMed publication note by removing older phrasing.SummaryDifference0.2%

- Check21 days agoChange DetectedThe page removed the government operating status notice and deleted the 'Head and neck squamous cell carcinoma' topic and the 'MedlinePlus Genetics' related topics section.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded related topic links for 'Head and neck squamous cell carcinoma' and 'MedlinePlus Genetics' to the page.SummaryDifference0.1%

- Check35 days agoChange DetectedNo substantial modifications detected in the study details page; the layout and key data appear the same across screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedAdded new MedlinePlus Genetics topic: Head and neck squamous cell carcinoma, expanding the page’s coverage of genetic information on a high-interest medical condition.SummaryDifference0.5%

Stay in the know with updates to Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.